NetApp Customers Say Hybrid Cloud is the Future of Enterprise IT in New Global Survey
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today revealed findings from its survey assessing the adoption of hybrid cloud strategies and operational focus areas among NetApp’s global enterprise customer base.
The survey of IT decision makers and infrastructure owners around the world found that 77 percent plan to operate their businesses in hybrid cloud environments for the foreseeable future in order to meet growing business demands for faster innovation, while optimizing operations and lowering infrastructure costs.
“Speed is the new scale. IT leaders everywhere are accelerating digital transformation efforts, requiring more agility and flexibility to stay ahead of their competition and deliver immediate business impact,” said Ronen Schwartz, General Manager and Senior Vice President, Cloud Volumes at NetApp. “Enterprises are embracing hybrid cloud models to effectively scale out IT resources to support business-critical applications and workloads – and NetApp is leading the industry in providing hybrid multi-cloud solutions to meet these organizations wherever they are.”
Highlights from NetApp’s 2021 Hybrid Cloud Enterprise Customer Adoption Survey include:
-
The Future is Hybrid Cloud: More than three-quarters of respondents said their organization plans to operate a hybrid cloud environment for the foreseeable future, while only 17 percent expect their organization to eventually migrate all IT to the cloud. Those surveyed listed the most important business benefits of hybrid cloud adoption to be:
- Faster Innovation - 26 percent
- Increased Responsiveness to Customers - 25 percent
- Increased Collaboration - 22 percent
- Key Operational Drivers for Hybrid Cloud Adoption: Respondents indicated they are looking to improve infrastructure flexibility and scale (27 percent), as hybrid cloud designs help IT teams get access to the on-demand and emerging technologies offered by public cloud while still leveraging legacy systems running reliably on-premises. Nearly a quarter (21 percent) said they needed to optimize costs, while 13 percent said they needed to improve data accessibility.
- Data Protection Remains Top Priority with Other Use Cases Gaining Traction: Data protection (including disaster recovery, backup and archiving) was the most popular hybrid cloud use case selected with 29 percent stating they are either utilizing hybrid cloud for data protection today or plan to within 24 months. However, customer respondents indicated they are also leveraging hybrid cloud for production use cases more than anticipated: 20 percent said they are currently integrating both on-premises and cloud resources to support the same workload for hybrid production, with 17 percent planning to do so within 24 months.
Innovative Organizations Continue to Succeed with NetApp Hybrid Cloud Solutions
The survey data shows that organizations all over the world are adopting a hybrid cloud strategy and relying on NetApp’s industry-leading solutions to accelerate their digital transformation and deliver business value faster.
“We needed the flexibility and agility of a hybrid cloud architecture to more effectively manage the massive amounts of data being generated daily across our global manufacturing facilities and development sites to accelerate time to insights and better inform decision making,” said Rohit Agrawal, Global Head of Hybrid Cloud at Siemens Healthineers. “NetApp’s hybrid cloud solutions help us streamline data center operations and keep costs under control, with the ability to centralize, manage, and secure the mission-critical data and applications.”
Methodology
The survey was conducted by NetApp among 79 organizations (54% AMER, 36% EMEA, 10% APAC) representing large and midsized organizations across diverse industries that have deployed or plan to deploy hybrid cloud architectures with NetApp.
Additional Resources
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005346/en/
Contact information
Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com
Investor Contact:
Lance Berger
NetApp
lance.berger@netapp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom